Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis/Introgen Adenoviral Gene Therapy In Phase III For Head/Neck Cancer

Executive Summary

A Phase III trial of Aventis and Introgen's p53 adenoviral gene therapy is underway for the treatment of head and neck cancer.

You may also be interested in...



Aventis Spins Off Gene Therapy, Returns p53 Commercial Rights To Introgen

Aventis is reducing its direct involvement in gene therapy research with a spin off of its Gencell division and return of responsibility for worldwide development of p53 gene products to Texas biotech firm Introgen.

Aventis Spins Off Gene Therapy, Returns p53 Commercial Rights To Introgen

Aventis is reducing its direct involvement in gene therapy research with a spin off of its Gencell division and return of responsibility for worldwide development of p53 gene products to Texas biotech firm Introgen.

FDA Planning More Inspections Of Gene Therapy Trials During IND Phase

FDA plans to step up inspections of gene therapy trials while they are in the IND phase, FDA Office of Therapeutics Research & Review Director Jay Siegel, MD, told the Senate Health/Public Health Subcommittee during a Feb. 2 hearing on gene therapy.

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel